PATENT-2 data release
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Japan submission
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan
FDA priority review
U. S. FDA Grants Priority Review to Bayer’s Riociguat for the Treatment of two Life-Threatening Pulmonary Hypertension Indications
CHEST-2 Data Release
Interim results from CHEST-2 study support benefits of Bayer’s Riociguat as demonstrated in Phase III CHEST-1 study
U.S. and EU Submission
Bayer’s Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension Submitted For Regulatory Approval in the U.S. and EU
CHEST data release
Bayer’s Riociguat first drug to demonstrate efficacy in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
PATENT data release
Bayer’s Riociguat Meets Primary Endpoint in Pivotal Phase III Study in Patients with Pulmonary Arterial Hypertension
Living with Pulmonary Hypertension
Embed this video:
My breathtaking story
Embed this video:
Dying to Breathe
Embed this video:
Rare Disease Day 2012
Embed this video:
Pulmonary hypertension (PH) is a rare but potentially deadly disorder of the heart and the lungs. There are five types of PH; each can affect the patient in a different way and every patient may have a different etiology and manifestation of PH.
High Definition Download Link
Pulmonary hypertension (PH) is a severe, progressive and life-threatening disorder in which the pressure in the pulmonary arteries is significantly increased and which can lead to heart failure and death.
High Definition Download Link
The most common symptoms of PH include shortness of breath, particularly upon physical exercise, fatigue, dizziness and fainting, all of which are worsened by exertion.
High Definition Download Link
Early pulmonary hypertension (PH) is often asymptomatic and, by the time symptoms appear, disease progression is usually well advanced and not entirely reversible.
High Definition Download Link
People with pulmonary hypertension (PH) develop a markedly decreased exercise. tolerance and reduced quality of life. PH can affect people of all ages, including children, though the average age at diagnosis is 50 years.
High Definition Download Link
A definitive diagnosis of pulmonary hypertension (PH) requires inserting a special pressure-sensing catheter into the right side of the heart (right heart catheterization).
High Definition Download Link
The recommended standard treatment for chronic thromboembolic pulmonary hypertension (CTEPH) is pulmonary endarterectomy (PEA), a surgical procedure in which the blood vessels of the lungs are cleared of clot and scar material, although 20-40% of patients are inoperable.
High Definition Download Link
Clots removed from a chronic thromboembolic pulmonary hypertension (CTEPH) patient following pulmonary endarterectomy (PEA).
High Definition Download Link
The three molecular pathways of pulmonary hypertension (PH). PH is associated with endothelial dysfunction, impaired synthesis of NO and insufficient stimulation of the NO-sGC-cGMP pathway.
High Definition Download Link
Pulmonary hypertension (PH) is associated with increased pulmonary artery pressure and endothelial dysfunction. As a result, the right side of the heart has to work harder to pump blood through the arteries.
High Definition Download Link
PH is characterized by morphological changes to the endothelium of the arteries of the lungs causing remodelling of the tissue, vasoconstriction and thrombosis-in-situ.
High Definition Download Link
The chemical messenger (signalling molecule) called cyclic guanosine monophosphate (cGMP) plays an important role in regulating vascular tone, proliferation, fibrosis, and inflammation.
High Definition Download Link
The ability of riociguat to directly stimulate the enzyme called soluble guanylate cyclase (sGC) independently of nitric oxide (NO), while also increasing the sensitivity of sGC to NO, leads to increased generation of cyclic guanosine monophosphate (cGMP).
High Definition Download Link
Professor Ardeschir Ghofrani, Lead Investigator of PATENT-1 and CHEST-1 studies, University Hospital Giessen, Germany.
High Definition Download Link
CONTACT
Riociguat Mode of Action
